Feroz Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Feroz Ahmad has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- David S. Leake
School of Biological Sciences, University of Reading, Reading RG6 6UB, UK
4 shared publications David S. Leake
Institute of Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom
2 shared publications- Nahida Tabassum
Department of Pharmaceutical Sciences University of Kashmir Srinagar Jammu and Kashmir India
2 shared publications - Amanpreet Kaur
School of Biological Sciences and Institute for Cardiovascular and Metabolic Research, University of Reading, Reading RG6 6UR, UK
1 shared publication - Ana M. Cruz
Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK
1 shared publication - Andrew Parnell
Micregen Ltd. Thames Valley Science Park, Reading, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 22 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 20
Inhibition of Low-Density Lipoprotein Oxidation by Cysteamine, Cystamine, Cysteine and Cystine at Lysosomal pH and pH 7.4
LDL can be oxidised in the lysosomes of macrophages. Cysteamine, a thiol antioxidant that accumulates in lysosomes, inhibits the oxidation of LDL by iron at lysosomal pH (pH 4.5) and protects against atherosclerosis in mice. We have investigated the effects of cysteamine and its related thiol cysteine and their disulfides on LDL oxidation by iron or copper at both pH 4.5 and 7.4. The oxidation of LDL by ferrous iron (5 µM) at pH 4.5 was delayed 12.9-fold by 100 µM cysteamine and 5.6-fold by 100 µM cysteine. Cystamine and cystine (the disulfide oxidation products of cyteamine and cysteine, respectively) did not inhibit LDL oxidation by ferrous iron at pH 4.5. LDL oxidation by 5 µM copper at pH 4.5 was delayed about 2-fold by 100 µM of the thiols cysteamine and cysteine, but there was little effect of the disulfides cystamine and cystine. Cysteamine and cystine did not inhibit the oxidation of LDL by ferrous iron at pH 7.4 in a MOPS buffer and even accelerated LDL oxidation later in the incubation. Cysteine initially inhibited the oxidation of LDL by ferrous iron at pH 7.4, but increased it later. LDL oxidation by copper at pH 7.4 was delayed 7.8-fold by 100 µM cysteamine. Cysteine delayed LDL oxidation by copper at pH 7.4 to a similar extent as cysteamine but, unlike cysteamine, continued to decrease the rate of oxidation even after the period of total inhibition had ended. Cystamine had no effect on LDL oxidation by copper at pH 7.4, but cystine partially inhibited LDL oxidation. The effects of thiols and disulfides on LDL oxidation, therefore, depend not only on the metal ion catalysing the oxidation but also on the pH of the environment.
- 22 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 20
Open AccessInhibition of Low-Density Lipoprotein Oxidation by Cysteamine, Cystamine, Cysteine and Cystine at Lysosomal pH and pH 7.4
LDL can be oxidised in the lysosomes of macrophages. Cysteamine, a thiol antioxidant that accumulates in lysosomes, inhibits the oxidation of LDL by iron at lysosomal pH (pH 4.5) and protects against atherosclerosis in mice. We have investigated the effects of cysteamine and its related thiol cysteine and their disulfides on LDL oxidation by iron or copper at both pH 4.5 and 7.4. The oxidation of LDL by ferrous iron (5 µM) at pH 4.5 was delayed 12.9-fold by 100 µM cysteamine and 5.6-fold by 100 µM cysteine. Cystamine and cystine (the disulfide oxidation products of cyteamine and cysteine, respectively) did not inhibit LDL oxidation by ferrous iron at pH 4.5. LDL oxidation by 5 µM copper at pH 4.5 was delayed about 2-fold by 100 µM of the thiols cysteamine and cysteine, but there was little effect of the disulfides cystamine and cystine. Cysteamine and cystine did not inhibit the oxidation of LDL by ferrous iron at pH 7.4 in a MOPS buffer and even accelerated LDL oxidation later in the incubation. Cysteine initially inhibited the oxidation of LDL by ferrous iron at pH 7.4, but increased it later. LDL oxidation by copper at pH 7.4 was delayed 7.8-fold by 100 µM cysteamine. Cysteine delayed LDL oxidation by copper at pH 7.4 to a similar extent as cysteamine but, unlike cysteamine, continued to decrease the rate of oxidation even after the period of total inhibition had ended. Cystamine had no effect on LDL oxidation by copper at pH 7.4, but cystine partially inhibited LDL oxidation. The effects of thiols and disulfides on LDL oxidation, therefore, depend not only on the metal ion catalysing the oxidation but also on the pH of the environment.
- Open Access
- 21 September 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (18) , e017524
Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
Background: We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is of more relevance to the treatment of human disease. Methods and Results: LDL receptor–deficient mice were fed a high‐fat diet to induce atherosclerotic lesions. They were then reared on chow diet and drinking water containing cysteamine or plain drinking water. Aortic atherosclerosis was assessed, and samples of liver and skeletal muscle were analyzed. There was no regression of atherosclerosis in the control mice, but cysteamine caused regression of between 32% and 56% compared with the control group, depending on the site of the lesions. Cysteamine substantially increased markers of lesion stability, decreased ceroid, and greatly decreased oxidized phospholipids in the lesions. The liver lipid levels and expression of cluster of differentiation 68, acetyl–coenzyme A acetyltransferase 2, cytochromes P450 (CYP)27, and proinflammatory cytokines and chemokines were decreased by cysteamine. Skeletal muscle function and oxidative fibers were increased by cysteamine. There were no changes in the plasma total cholesterol, LDL cholesterol, high‐density lipoprotein cholesterol, or triacylglycerol concentrations attributable to cysteamine. Conclusions: Inhibiting the lysosomal oxidation of LDL in atherosclerotic lesions by antioxidants targeted at lysosomes causes the regression of atherosclerosis and improves liver and muscle characteristics in mice and might be a promising novel therapy for atherosclerosis in patients.
- 21 September 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (18) , e017524
Open AccessCysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
Background: We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is of more relevance to the treatment of human disease. Methods and Results: LDL receptor–deficient mice were fed a high‐fat diet to induce atherosclerotic lesions. They were then reared on chow diet and drinking water containing cysteamine or plain drinking water. Aortic atherosclerosis was assessed, and samples of liver and skeletal muscle were analyzed. There was no regression of atherosclerosis in the control mice, but cysteamine caused regression of between 32% and 56% compared with the control group, depending on the site of the lesions. Cysteamine substantially increased markers of lesion stability, decreased ceroid, and greatly decreased oxidized phospholipids in the lesions. The liver lipid levels and expression of cluster of differentiation 68, acetyl–coenzyme A acetyltransferase 2, cytochromes P450 (CYP)27, and proinflammatory cytokines and chemokines were decreased by cysteamine. Skeletal muscle function and oxidative fibers were increased by cysteamine. There were no changes in the plasma total cholesterol, LDL cholesterol, high‐density lipoprotein cholesterol, or triacylglycerol concentrations attributable to cysteamine. Conclusions: Inhibiting the lysosomal oxidation of LDL in atherosclerotic lesions by antioxidants targeted at lysosomes causes the regression of atherosclerosis and improves liver and muscle characteristics in mice and might be a promising novel therapy for atherosclerosis in patients.
- Open Access
- 1 December 2019
- Published by Elsevier in Atherosclerosis
- Vol. 291, 9-18
Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice
- 1 December 2019
- Published by Elsevier in Atherosclerosis
- Vol. 291, 9-18
Open AccessCysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice
- Open Access
- 1 January 2019
- Published by Elsevier in Journal of Lipid Research
- Vol. 60 (1) , 98-110
Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages
- 1 January 2019
- Published by Elsevier in Journal of Lipid Research
- Vol. 60 (1) , 98-110
Open AccessLysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages
- Open Access
- 12 September 2018
- Published by SAGE Publications in Innate Immunity
- Vol. 24 (7) , 411-421
The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling
TLRs, including TLR4, have been shown to play a crucial role in cardiovascular inflammatory-based diseases. The main goal of this study was to determine the potential of FP7, a synthetic glycolipid active as a TLR4 antagonist, to modulate haematopoietic and non-haematopoietic vascular TLR4 pro-inflammatory signalling. HUVEC, human THP-1 monocytes, THP-1-derived macrophages, mouse RAW-264.7 macrophages and Angiotensin II-infused apolipoprotein E-deficient mice were in vitro and in vivo models, respectively. Western blotting, Ab array and ELISA approaches were used to explore the effect of FP7 on TLR4 functional activity in response to bacterial LPS (in vitro) and endogenous ligands of sterile inflammation (in vitro and in vivo). Following activation of TLR4, in vitro and in vivo data revealed that FP7 inhibited p38 MAPK and p65 NF-kB phosphorylation associated with down-regulation of a number of TLR4-dependent pro-inflammatory proteins. In addition to inhibition of LPS-induced TLR4 signalling, FP7 negatively regulated TLR4 activation in response to ligands of sterile inflammation (hydroperoxide-rich oxidised LDL, in vitro and Angiotensin II infusion, in vivo). These results demonstrate the ability of FP7 to negatively regulate in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling both in humans and mice, suggesting the potential therapeutic use of this TLR4 antagonist for pharmacological intervention of vascular inflammatory diseases.
- 12 September 2018
- Published by SAGE Publications in Innate Immunity
- Vol. 24 (7) , 411-421
Open AccessThe synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling
TLRs, including TLR4, have been shown to play a crucial role in cardiovascular inflammatory-based diseases. The main goal of this study was to determine the potential of FP7, a synthetic glycolipid active as a TLR4 antagonist, to modulate haematopoietic and non-haematopoietic vascular TLR4 pro-inflammatory signalling. HUVEC, human THP-1 monocytes, THP-1-derived macrophages, mouse RAW-264.7 macrophages and Angiotensin II-infused apolipoprotein E-deficient mice were in vitro and in vivo models, respectively. Western blotting, Ab array and ELISA approaches were used to explore the effect of FP7 on TLR4 functional activity in response to bacterial LPS (in vitro) and endogenous ligands of sterile inflammation (in vitro and in vivo). Following activation of TLR4, in vitro and in vivo data revealed that FP7 inhibited p38 MAPK and p65 NF-kB phosphorylation associated with down-regulation of a number of TLR4-dependent pro-inflammatory proteins. In addition to inhibition of LPS-induced TLR4 signalling, FP7 negatively regulated TLR4 activation in response to ligands of sterile inflammation (hydroperoxide-rich oxidised LDL, in vitro and Angiotensin II infusion, in vivo). These results demonstrate the ability of FP7 to negatively regulate in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling both in humans and mice, suggesting the potential therapeutic use of this TLR4 antagonist for pharmacological intervention of vascular inflammatory diseases.
- Open Access
- 1 July 2018
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 213, 13-24
Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed
- 1 July 2018
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 213, 13-24
Open AccessAntioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e51
Lysosomal oxidation of LDL and its implications for atherosclerosis
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e51
Lysosomal oxidation of LDL and its implications for atherosclerosis
- Open Access
- 1 June 2013
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 5 (2) , 54-59
Pharmacognostic standardization, antioxidant and free radical scavenging activity of the seeds of Triticum aestivum L - A dietary staple
To establish the Quality standards of Triticum aestivum L, seeds as per WHO guidelines. To study the antioxidant and hepatoprotective profile of T. aestivum L. seeds. Pharmacognostic studies like morphological, microscopical, physico-chemical, phytochemical evaluation, fluorescence analysis, TLC, HPTLC, phytochemical analysis etc. of various extracts of the seeds of T. aestivum were carried out as per established methods. The ethanolic extract was evaluated for antioxidant and hepatoprotective activity using rat model. Preliminary phytochemical analysis mainly revealed the presence of carbohydrates, phenolics, proteins, resins, lipids and flavonoids. T. aestivum at different doses, i.e. 5-45 μg/ml showed free radical scavenging activity in dose dependent manner. The amount of phenolic components was found to be 313.5 μg/mg indicating considerable antioxidant activity. The ethanolic extract of T. aestivum was administered at dose level of 100 mg/kg/day, every day for 21 days along with CCl4. Biochemical and histopathological results conclude that the seeds have hepatoprotective activity.
- 1 June 2013
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 5 (2) , 54-59
Open AccessPharmacognostic standardization, antioxidant and free radical scavenging activity of the seeds of Triticum aestivum L - A dietary staple
To establish the Quality standards of Triticum aestivum L, seeds as per WHO guidelines. To study the antioxidant and hepatoprotective profile of T. aestivum L. seeds. Pharmacognostic studies like morphological, microscopical, physico-chemical, phytochemical evaluation, fluorescence analysis, TLC, HPTLC, phytochemical analysis etc. of various extracts of the seeds of T. aestivum were carried out as per established methods. The ethanolic extract was evaluated for antioxidant and hepatoprotective activity using rat model. Preliminary phytochemical analysis mainly revealed the presence of carbohydrates, phenolics, proteins, resins, lipids and flavonoids. T. aestivum at different doses, i.e. 5-45 μg/ml showed free radical scavenging activity in dose dependent manner. The amount of phenolic components was found to be 313.5 μg/mg indicating considerable antioxidant activity. The ethanolic extract of T. aestivum was administered at dose level of 100 mg/kg/day, every day for 21 days along with CCl4. Biochemical and histopathological results conclude that the seeds have hepatoprotective activity.
- 1 January 2013
- Published by Medknow in Asian Pacific Journal of Tropical Biomedicine
- Vol. 3 (1) , 64-68
Preliminary phytochemical, acute oral toxicity and antihepatotoxic study of roots of Paeonia officinalis Linn.
To carry out a preliminary phytochemical, acute oral toxicity and antihepatotoxic study of the roots of Paeonia officinalis (P. officinalis) L. Preliminary phytochemical investigation was done as per standard procedures. Acute oral toxicity study was conducted as per OECD 425 guidelines. The antihepatotoxic activity of aqueous extract of root of P. officinalis was evaluated against carbon tetrachloride (CCl4) induced hepatic damage in rats. Aqueous extract of P. officinalis at the dose levels of 100 and 200 mg/kg body weight was administered daily for 14 d in experimental animals. Liver injury was induced chemically, by CCl4 administration (1 mL/kg i.p.). The hepatoprotective activity was assessed using various biochemical parameters like aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum alkaline phosphatase (SALP), total bilirubin and total protein (TP) along with histopathological studies. Phytochemical screening revealed that the roots of P. officinalis contain alkaloids, tannins, saponins, glycosides, carbohydrates, flavonoids, terpenes, steroids and proteins. The aqueous extract did not cause any mortality up to 2 000 mg/kg. In rats that had received the root extract at the dose of 100 and 200 mg/kg, the substantially elevated AST, ALT, SALP, total bilirubin levels were significantly lowered, respectively, in a dose dependent manner, along with CCl4 while TP levels were elevated in these groups. Histopathology revealed regeneration of the livers in extract treated groups while Silymarin treated rats were almost normal. The aqueous extract of P. officinalis is safe and possesses antihepatotoxic potential.
- 1 January 2013
- Published by Medknow in Asian Pacific Journal of Tropical Biomedicine
- Vol. 3 (1) , 64-68
Preliminary phytochemical, acute oral toxicity and antihepatotoxic study of roots of Paeonia officinalis Linn.
To carry out a preliminary phytochemical, acute oral toxicity and antihepatotoxic study of the roots of Paeonia officinalis (P. officinalis) L. Preliminary phytochemical investigation was done as per standard procedures. Acute oral toxicity study was conducted as per OECD 425 guidelines. The antihepatotoxic activity of aqueous extract of root of P. officinalis was evaluated against carbon tetrachloride (CCl4) induced hepatic damage in rats. Aqueous extract of P. officinalis at the dose levels of 100 and 200 mg/kg body weight was administered daily for 14 d in experimental animals. Liver injury was induced chemically, by CCl4 administration (1 mL/kg i.p.). The hepatoprotective activity was assessed using various biochemical parameters like aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum alkaline phosphatase (SALP), total bilirubin and total protein (TP) along with histopathological studies. Phytochemical screening revealed that the roots of P. officinalis contain alkaloids, tannins, saponins, glycosides, carbohydrates, flavonoids, terpenes, steroids and proteins. The aqueous extract did not cause any mortality up to 2 000 mg/kg. In rats that had received the root extract at the dose of 100 and 200 mg/kg, the substantially elevated AST, ALT, SALP, total bilirubin levels were significantly lowered, respectively, in a dose dependent manner, along with CCl4 while TP levels were elevated in these groups. Histopathology revealed regeneration of the livers in extract treated groups while Silymarin treated rats were almost normal. The aqueous extract of P. officinalis is safe and possesses antihepatotoxic potential.
- Open Access
- 1 January 2011
- Published by Manuscript Technomedia LLP in Pharmacognosy Reviews
- Vol. 5 (9) , 30-40
Role of natural herbs in the treatment of hypertension
Hypertension (HTN) is the medical term for high blood pressure. It is dangerous because it makes the heart work too hard and contributes to atherosclerosis (hardening of arteries), besides increasing the risk of heart disease and stroke. HTN can also lead to other conditions such as congestive heart failure, kidney disease, and blindness. Conventional antihypertensives are usually associated with many side effects. About 75 to 80% of the world population use herbal medicines, mainly in developing countries, for primary health care because of their better acceptability with human body and lesser side effects. In the last three decades, a lot of concerted efforts have been channeled into researching the local plants with hypotensive and antihypertensive therapeutic values. The hypotensive and antihypertensive effects of some of these medicinal plants have been validated and others disproved. However, ayurvedic knowledge needs to be coupled with modern medicine and more scientific research needs to be done to verify the effectiveness, and elucidate the safety profile of such herbal remedies for their antihypertensive potential.
- 1 January 2011
- Published by Manuscript Technomedia LLP in Pharmacognosy Reviews
- Vol. 5 (9) , 30-40
Open AccessRole of natural herbs in the treatment of hypertension
Hypertension (HTN) is the medical term for high blood pressure. It is dangerous because it makes the heart work too hard and contributes to atherosclerosis (hardening of arteries), besides increasing the risk of heart disease and stroke. HTN can also lead to other conditions such as congestive heart failure, kidney disease, and blindness. Conventional antihypertensives are usually associated with many side effects. About 75 to 80% of the world population use herbal medicines, mainly in developing countries, for primary health care because of their better acceptability with human body and lesser side effects. In the last three decades, a lot of concerted efforts have been channeled into researching the local plants with hypotensive and antihypertensive therapeutic values. The hypotensive and antihypertensive effects of some of these medicinal plants have been validated and others disproved. However, ayurvedic knowledge needs to be coupled with modern medicine and more scientific research needs to be done to verify the effectiveness, and elucidate the safety profile of such herbal remedies for their antihypertensive potential.